Dyax Corp.
News published by Dyax Corp. officials updates activities
Published in Medical Verdicts and Law Weekly, May 31st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Dyax Corp..
Report 1: Dyax Corp. (Nasdaq:DYAX) announced that patient treatment has begun in the Phase 3 confirmatory trial, known as EDEMA4, for its lead product candidate, DX-88 (ecallantide). DX-88, an internally discovered, recombinant, plasma kallikrein inhibitor, is in clinical trials for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disease characterized by episodes of acute swelling and inflammation. Dyax is also initiating a Phase 2 clinical trial of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- AdvaMed
Advamed Commends Passage of FDA Revitalization Act - Advanced Magnetics, Inc.
Advanced Magnetics Announces Proposed Public Offering of Common Stock - Alliance HealthCard, Inc.
Alliance HealthCard 2Q Profit Rises 57 Percent - Alliance Imaging, Inc.
Alliance Imaging Announces Sale of Stock by a Stockholder - Alzheimer Disease
Interim report for the first quarter of 2007 - Alzheimer Disease
Shire welcomes early date for Judicial Review of NICE decision on Alzheimer's treatments - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
